LRRK2 mutation carriers without manifest Parkinson's disease (n=25) had greater <sup>18</sup>F-FDOPA uptake and dopamine transporter binding than did individuals with sporadic Parkinson's disease, with <sup>18</sup>F-FDOPA uptake comparable with controls and dopamine transporter binding lower than in controls.